VertebrOpLasty Versus Conservative Treatment in Acute Non Osteoporotic Vertebral Fractures
Launched by UNIVERSITY HOSPITAL, CLERMONT-FERRAND · Jul 17, 2012
Trial Information
Current as of June 01, 2025
Completed
Keywords
ClinConnect Summary
The study is a prospective, randomized trial comparing conservative treatment (brace) and vertebroplasty in acute (less than 15 days after trauma) traumatic vertebral compression fracture (VCF) type A according Magerl classification
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 18 - 70 year old
- • volunteers
- • Vertebral compression fractures Magerl type A
- • Acute Trauma (less than 15 days)
- • Between T5 and L5
- • Patient able to undergo both vertebroplasty and conservative treatment
- • Consent form obtained
- Exclusion Criteria:
- • Neural arch fracture
- • C1 to T4 fracture
- • Neurologic symptoms caused by the fracture
- • Encephalic trauma with Glasgow Coma Scale less than 15
- • Ongoing cancer
- • Routine painkillers intake
- • Local or systemic infection
- • Coagulation's disorder
- • Pregnancy
- • Involvement in an another clinical trial
About University Hospital, Clermont Ferrand
The University Hospital of Clermont-Ferrand is a leading academic medical institution dedicated to advancing healthcare through innovative research and clinical trials. Renowned for its multidisciplinary approach, the hospital integrates cutting-edge scientific inquiry with patient care, fostering an environment that promotes collaboration among healthcare professionals, researchers, and academic partners. With a strong commitment to improving patient outcomes, the institution actively engages in a wide array of clinical studies, ranging from early-phase trials to large-scale interventions, aimed at addressing critical health challenges and enhancing treatment modalities. Its state-of-the-art facilities and expertise make it a pivotal contributor to clinical research in the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Clermont Ferrand, , France
Patients applied
Trial Officials
Emmanuel CHABERT
Principal Investigator
University Hospital, Clermont-Ferrand
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials